BGLAF (BioGaia AB) Accounts Payable & Accrued Expense: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BGLAF BioGaia AB BGLAF
100 GF Score
Price $11.55
GF Value $13.18
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioGaia AB Accounts Payable & Accrued Expense?

BioGaia AB BGLAF 100 Accounts Payable & Accrued Expense is $0.0 Mil as of Jun. 2026. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.18 (Modestly Undervalued). The stock has 3 warning signs investors should review.

BioGaia AB's quarterly accounts payable & accrued expense declined from Dec. 2025 ($7.1 Mil) to Mar. 2026 ($0.0 Mil) but then stayed the same from Mar. 2026 ($0.0 Mil) to Jun. 2026 ($0.0 Mil).

BioGaia AB's annual accounts payable & accrued expense declined from Dec. 2023 ($8.3 Mil) to Dec. 2024 ($7.7 Mil) and declined from Dec. 2024 ($7.7 Mil) to Dec. 2025 ($7.1 Mil).

BioGaia AB Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for BioGaia AB's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGaia AB Accounts Payable & Accrued Expense Chart

BioGaia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.52 5.28 8.29 7.70 7.08

BioGaia AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 7.08 0.00 0.00
BGLAF
100GF Score
BioGaia AB BGLAF
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioGaia AB Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of $0.0 Mil mean?
BioGaia AB (BGLAF) has a Accounts Payable & Accrued Expense of $0.0 Mil as of Jun. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on BioGaia AB and its competitors.
Is BioGaia AB's Accounts Payable & Accrued Expense too high?
BioGaia AB's current Accounts Payable & Accrued Expense is $0.0 Mil. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Accounts Payable & Accrued Expense compare to ZTS?
BioGaia AB's Accounts Payable & Accrued Expense of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Drug Manufacturers company?
A good Accounts Payable & Accrued Expense depends on the Drug Manufacturers industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on BioGaia AB and its competitors. BioGaia AB's current Accounts Payable & Accrued Expense is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.18, compared to a current price of $11.55 — trading 12.4% below its estimated fair value. The current Accounts Payable & Accrued Expense is $0.0 Mil. BioGaia AB's overall GF Score™ is 100/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Accounts Payable & Accrued Expense is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioGaia AB (BGLAF) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued. The current stock price of $11.55 is trading 12.4% below its estimated GF Value™ of $13.18. GuruFocus considers BioGaia AB to be Modestly Undervalued.

Key valuation signals for BGLAF:

  • Accounts Payable & Accrued Expense: $0.0 Mil
  • GF Value™: $13.18 vs. price of $11.55 (12.4% below fair value)
  • GF Score™: 100/100 with 3 warning signs

No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioGaia AB Business Description

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score

Get the complete analysis for BGLAF

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.55
Price
$13.18
GF Value